Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

Testosterone replacement therapy in men with low serum T and untreated prostate cancer

An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer. … READ MORE …

Castrate serum T levels and prostate cancer-specific mortality

A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer. … READ MORE …

Pretreatment T level and post-surgical pathologic stage: a prognostic relationship?

A new study by a French research team has suggested that there may be a prognostic relationship between the pretreatment testosterone (T) level and the post-surgical pathology of men who undergo radical prostatectomy (RP) for treatment of localized prostate cancer. … READ MORE